date:Apr 26, 2012
roduct on its own merits and to not make broad, general assumptions about the safety of nanotechnology products.
FDAs current approach to regulation of nanotechnology products
The FDA currently embraces a one size does not fit all approach to regulating nanotechnology.
According to the FDA, it is necessary for technical assessments to be product-specific, taking into account the effects of nanomaterials in the particular biological and mechanical context of each product and its intended use